cancercaspasecell deathDAMPsimmunogenic cell deathinterferonImmunogenic cell death (ICD) is a form of cell death that can engage immunity. Therapeutic engagement of ICD in cancer may lead to more effective responses by eliciting antitumor immunity. Here, we discuss various modalities of ICD, ...
While current cancer therapies rely heavily on apoptosis — a largely immunologically silent form of cell death — there is growing interest in harnessing immunogenic forms of cell death such as necroptosis. Unlike apoptosis, necroptosis generates second messengers that act on immune cells in the ...
Immunogenic cell death (ICD), which results from insufficient cellular adaptation to specific stressors, occupies a central position in the development of novel anticancer treatments. Several therapeutic strategies to elicit ICD — either as standalone a
The past decade has witnessed major breakthroughs in cancer immunotherapy. This development has been largely motivated by cancer cell evasion of immunological control and consequent tumor resistance to conventional therapies. Immunogenic cell death (ICD) is considered one of the most promising ways to ac...
In recent decades, immunogenic cell death (ICD) has received considerable research attention. ICD is accompanied by the release and chronic exposure of damage-associated molecular patterns (DAMPs), conferring a potent adjuvanticity to dying cancer cells. ROS production and endoplasmic reticulum (ER) ...
Cancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cell lung cancer. Programmed death receptor-1/programmed death receptor ligand-1 (PD-1
In recent decades, immunogenic cell death (ICD) has received considerable research attention. ICD is accompanied by the release and chronic exposure of damage-associated molecular patterns (DAMPs), conferring a potent adjuvanticity to dying cancer cells. ROS production and endoplasmic reticulum (ER) ...
Focus was initially placed on targeting cancers considered immunogenic such as melanoma, renal and lung cancers but subsequently the application expanded to include amongst others Hodgkin Lymphoma, urothelial as well as head and neck cancer. This article provides a comprehensive review of the early and...
Cancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cell lung cancer. Programmed death receptor-1/programmed death receptor ligand-1 (PD-1
Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013). CAS PubMed Google Scholar Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 15, 1170–1178 (2009). CAS...